This frameshift mutation resulted in a 40% cumulative risk of developing breast cancer by age 70 (95% CI, 17–77) (61), similar to that for BRCA2 mutation carriers (~45%; 95% CI, 31–56) (62), implying a striking role of PALB2 in predisposition to breast cancer. This evidence concerns the gene PALB2 and breast carcinoma.